Categories Earnings, LATEST

Lyft (LYFT) beats Q3 revenue estimates; raises full-year outlook

Lyft Inc. (NASDAQ: LYFT) beat revenue estimates and reported a narrow-than-expected loss for the third quarter of 2019. The company also raised its full-year 2019 outlook. Despite the win, shares were down 2% in aftermarket hours on Wednesday.  

Total revenues rose 63% to $956 million from the year-ago period, beating estimates of $913 million.  

Lyft active riders and revenue per active rider quarterly growth trend

Net loss was $463.5 million, or $1.57 per share, compared to $249.2 million, or $11.58 per share, in the prior-year quarter. Adjusted net loss was $121.6 million, or $0.41 per share. Analysts had forecast a loss of $1.66 per share.

Logan Green, Co-founder and Chief Executive Officer said, “Our continued focus on consumer transportation is yielding meaningful improvements in monetization and strong operating leverage. As a result of the continued strength of our execution, we are updating our outlook for 2019. Importantly, we now expect to be profitable on an adjusted EBITDA basis in the fourth quarter of 2021.”

During the quarter, the company reported a 28% increase in active riders to 22.3 million. Revenue per active rider increased 27% to $42.82.

Also read: Lyft Q3 2019 Earnings Preview

Lyft reported contribution of $479.2 million, reflecting an increase of 82% year-over-year. Contribution margin increased to 50.1% from 45% last year.

For the fourth quarter of 2019, Lyft expects revenues to grow 46-47% to a range of $975-985 million.

For full-year 2019, the company raised its outlook and now expects revenues to grow around 66% to a range of between $3.57 billion and $3.58 billion. This compares to the previous guidance range of $3.47 billion to $3.50 billion, reflecting a growth of 61-62%.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top